ABSTRACT: By, in effect, rendering pharmacokinetics an exper-14 imentally adjustable parameter, the ability to perform feedback- accurately simulate human pharmacokinetics in animal models, and (4) measure minute-to-minute changes in a drug's 28 pharmacokinetic behavior in response to changing health status, diet, drug−drug interactions, or other intrinsic and external 29 factors. In the clinic, feedback-controlled drug delivery would improve our ability to accurately maintain therapeutic drug levels 30 in the face of large, often unpredictable intra-and interpatient metabolic variation. This, in turn, would improve the efficacy and 31 safety of therapeutic intervention, particularly for the most gravely ill patients, for whom metabolic variability is highest and the 32 margin for therapeutic error is smallest. 
provided by an in vivo electrochemical aptamer-based (E-AB) sensor 23 to adjust dosing rates every 7 s. The resulting system supports the maintenance of either constant or predefined time-varying 24 plasma drug concentration profiles in live rats over many hours. For researchers, the resultant high-precision control over drug 25 plasma concentrations provides an unprecedented opportunity to (1) map the relationships between pharmacokinetics and 26 clinical outcomes, (2) eliminate inter-and intrasubject metabolic variation as a confounding experimental variable, (3) 27 accurately simulate human pharmacokinetics in animal models, and (4) measure minute-to-minute changes in a drug's 28 pharmacokinetic behavior in response to changing health status, diet, drug−drug interactions, or other intrinsic and external 29 factors. In the clinic, feedback-controlled drug delivery would improve our ability to accurately maintain therapeutic drug levels 30 in the face of large, often unpredictable intra-and interpatient metabolic variation. This, in turn, would improve the efficacy and 31 safety of therapeutic intervention, particularly for the most gravely ill patients, for whom metabolic variability is highest and the 32 margin for therapeutic error is smallest. 36 informed by high-frequency in vivo drug measurements would 37 find important applications in both pharmacological research 38 and in clinical practice. Such a technology would, for example, 39 allow researchers to treat pharmacokinetic variability as an 40 experimentally controllable parameter, enabling studies of the 41 reproducibility of therapeutic outcomes when such variability 42 is effectively eliminated (e.g., to make all animals in a test 43 cohort exhibit the same maximum drug concentration and the 44 same area under the curve). It would likewise enable the 45 accurate simulation of human pharmacokinetics in animal 46 models, rendering them better mimics of human physiol-47 ogy.
1−4 Ultimately, such a technology could similarly prove of 48 value in the clinic, where it could be used to optimize moment- 49 to-moment dosing in response to a patient's changing 50 metabolism, ensuring that a therapy's benefits are maximized 51 while its risks are minimized.
5−9 52
The potential scientific and clinical impact of feedback-53 controlled drug delivery has long been recognized. 5 sustained drug levels within ±5 μM of the specified Figure 1 . Closed-loop, feedback-controlled drug delivery. (A) E-AB sensors consist of an electrode-attached aptamer modified with a redox reporter (here methylene blue). Upon target binding the aptamer undergoes a conformational change that alters the rate of electron transfer from the reporter in a manner monotonically related to target concentration. 31 (B) With a diameter of ∼300 μm, E-AB sensors are small enough to deploy using a 22-gauge catheter; for the studies here we employed jugular placements. 32 (C) Using the realtime, seconds-resolved concentration information provided by such indwelling E-AB sensors as input to a feedback control algorithm we have here demonstrated the ability to actively adjust dosing rates every 7 s via an infusion pump delivering the drug into the opposite jugular. At each time point the controller computes the difference between the drug concentration reported by the sensor and a userdefined reference concentration and, based on proportional, integral, and derivative terms, calculates the precise drug dosing rate needed to best achieve the concentration desired at that moment. 151 concentration set points in all three using the same set of PID 152 gain parameters. This level of precision far exceeds that 153 achieved by the constant-rate drug infusions that are currently 154 state of the art for antibiotic dosing. 55, 56 For example, when we 155 perform constant-rate intravenous infusions of tobramycin (10 156 mg/kg) into two male rats (360 and 420 g) we observe far 157 poorer precision in reaching and maintaining constant plasma 158 drug concentrations ( Figure S3 ).
159
Using E-AB-driven feedback control we can easily achieve 160 the maintenance of constant plasma tobramycin concen-161 trations centered within the drug's narrow therapeutic window. 162 We demonstrated this by holding tobramycin at 10 times the 163 drug's minimum inhibitory concentration, a value below that 164 considered toxic in humans yet high enough to remain 165 effective. 55, 57 In this experiment we reached the desired 166 concentration within 30 min of the onset of control and then f3 167 actively held that concentration for 4 h ( Figure 3A ; Figure S4 ). 168 Of note, the time frame of this control was limited by the 169 maximum time we are allowed to keep animals under 170 anesthesia (to avoid toxic exposure to the anesthetic 171 isoflurane) and not by any failure of the sensor or the 172 resulting feedback control.
173
The controller maintains constant plasma drug levels even in 174 the face of significant metabolic variation ( Figure 3A ). 175 Moreover, its ability to do so provides a means of determining 176 the magnitude of this variation with unprecedented, minute-177 scale time resolution. Once plasma drug levels have reached 178 the desired concentration, the drug's instantaneous elimination 179 half-life, t 1/2 (in min), can be derived from the infusion rate, R 180 (in μg·min
182 where MW is the molecular weight of the drug in daltons, C P is 183 the drug's plasma concentration in molar units, and V D is the 184 volume of distribution (in liters), which can be determined 185 separately from the pharmacokinetic profiles of intravenous 186 injections ( Figure S5 ) and is assumed to be approximately 187 constant throughout the experiment. The resultant plot of the 188 drug's changing elimination half-life illustrates the significant 189 (here ∼3-fold) fluctuations seen for the metabolism (ex-190 cretion) of this drug in rats over the course of just a few hours 191 ( Figure 3B ), which presumably occurs due to increasing 192 kidney clearance associated with the intravenous fluid 193 delivered during dosing. 59,60 194 While the ability to maintain plasma drug levels at a fixed 195 value (e.g., centered within the therapeutic window) should be 196 demonstrate our ability to precisely achieve such profiles we . E-AB-driven feedback-controlled dosing supports unprecedentedly high-precision control over in vivo drug levels. Here, for example, we present feedback-controlled pharmacokinetic profiles in which the plasma tobramycin concentrations were held at set points of 80, 50, or 20 μM for 40, 50, and 60 min, respectively, in three different rats. The precision afforded by adjusting the dosing rate every 7 s using real-time concentration measurements is reflected in a variance of only a few micromolar around the desired concentration. Figure 3 . Feedback-controlled, multihour maintenance of therapeutic drug levels. PID-controlled drug infusions actively adjust dosing in response to metabolic fluctuations within a living subject. (A) Here, for example, we used feedback control to hold the plasma tobramycin level constant at a concentration 10-fold above the drug's MIC 90 (the minimum inhibitory concentration for 90% of clinical isolates 57 ) for approximately 4 h. (Longer runs are precluded due to animal welfare concerns that limit the time animals can be kept under anesthesia to avoid toxic exposure to the anesthetic gas isoflurane). (B) The elimination half-life of the drug, which can be determined from the instantaneous dosing rate required to maintain plasma concentrations at the desired concentration (eq 1), varies by more than a factor of 3 within this one subject over the course of this experiment, highlighting the need for improved drug delivery mechanisms. The black curve reflects a 3 min rolling average. 214 exhibited only 4% standard deviation despite similarly varying 215 in size and body surface area ( Figure 4B ).
216
To find the source of this improvement we performed 217 regression analyses of our data using a one compartment 218 pharmacokinetic model with first-order absorption and 219 elimination kinetics 58 and then calculated the relative standard 220 deviation between the pharmacokinetic parameters obtained 221 from the relevant pharmacokinetic profiles. Doing this we 222 determined that the improved precision we achieve originates 223 from actively adjusting dosing in response to fluctuations of the f5 224 rate of elimination ( Figure 5) ; in other words, our controller is 225 successfully responding to differences in the pharmacokinetics 226 of different rats to ensure that the total area under the curve 227 remains effectively identical between them.
228
A third potentially important research application of 229 feedback-controlled drug delivery would be to emulate 230 human drug exposure profiles in animal models. Such 231 "humanization" of animal pharmacokinetics would allow us 232 to determine the effects of human-like plasma drug-time 233 profiles (rather than the typically much more rapid uncon-234 strained pharmacokinetics of the animal) on diseases being 235 studied in animal models, such as infection with human 236 pathogens or the treatment of human xenograft tumors, and to 237 better determine the most effective dose in the face of 238 significant interspecies differences in drug pharmacokinetics. ( Figure 6 ). To achieve this, the PID-controller actively . Eliminating subject-to-subject variability in drug exposure. Intersubject metabolic variability can confound studies of the relationships between pharmacokinetics and therapeutic outcomes. The high precision control over in vivo drug levels afforded by E-AB-driven feedback control provides a means of circumventing this confounding variability. (A) As shown, for example, the intramuscular administration of empirically determined doses of tobramycin (by calibrating them against body surface area) 68 results in significant (30% standard deviation) subject-to-subject variability in drug exposure as measured by the area under the curve. (B) In contrast, PID-controlled delivery following a programmed pharmacokinetic function (here we imposed a one compartment pharmacokinetic model with first order drug absorption and elimination kinetics) results in an order of magnitude improvement in the precision with which the area under the curve can be reproduced between animals (4% standard deviation). Figure 5 . Feedback-controlled drug delivery greatly improves control over drug exposure. Here we present the relative standard deviation of four pharmacokinetic parameters determined by regression analysis of the profiles shown in Figure 4 : the area under the curve (AUC), the rate of drug absorption (γ abs. ), the maximum plasma concentration (C max ), and the rate of elimination (β elim ). From these plots it becomes evident that the order of magnitude improvement in the reproducibility of AUC between subjects that we achieve originates from actively adjusting dosing in response to fluctuations of the rate of elimination. In other words, since tobramycin is excreted unchanged via the kidneys (i.e., it is not metabolized within the body), our PIDcontroller is finely regulating dosing to match kidney clearance. We purchased the methylene-blue-and-thiol-modified DNA 351 from Biosearch Technologies, with sequence Figure 6 . "Humanizing" animal pharmacokinetics. PID-controlled delivery following a programmed pharmacokinetic function that emulates human drug exposure levels creates an unprecedented opportunity to account for interspecies metabolic differences and determine the effects of human-like plasma drug time profiles on human disease being studied in animal models. 
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Electrode Fabrication. The E-AB sensors employed in 357 this work were fabricated as described in previous reports.
32,79
358 Briefly, segments of pure gold (12 cm in length), platinum 359 (11.5 cm), and silver (11 cm) wire, were cut to make sensors. 360 The insulation at both ends of these wires, about 2 cm, was 361 removed using a surgical blade to allow electrical contact. 362 These were then soldered each to one of the three ends of a 363 connector cable using 60% tin/40% lead rosin-core solder (0.8 364 mm diameter) and then attached together by applying heat to 365 shrinkable tubing around the body of the wires, except for a 366 small window of about 5 mm at the edge of each wire. The 367 wires were attached in a layered fashion, with the gold wire 368 being insulated alone first, then both gold and platinum wires 369 together, and finally all three wires together. The purpose of 370 this three-layer-thick insulation was to give mechanical 371 strength to the body of the malleable probe. To prevent 372 electrical shorts between wires, different lengths were used for 373 each wire as described above. The sensor window (i.e., the 374 region devoid of insulation) in the gold wire was cut to 375 approximately 3 mm in length. To increase the surface area of 376 the gold working electrodes (to obtain larger peak currents) 377 the sensor surface was roughened electrochemically via 378 immersion in 0.5 M sulfuric acid followed by stepping the 379 potential between E initial = 0.0 V to E high = 2.0 V vs Ag/AgCl, 380 back and forth, for 16 000 pulses.
32 Each potential step was of 381 20 ms duration with no waiting time in-between pulses. To 382 fabricate sensors an aliquot of the DNA construct was reduced 383 for 30 min at room temperature with a 1000-fold molar excess 384 of tris(2-carboxyethyl)phosphine. A freshly roughened probe 385 was then rinsed in deionized water before being immersed in a 386 solution of the reduced DNA construct at 200 nM in PBS for 1 387 h at room temperature. Following this the sensor was 388 immersed overnight at 25°C for 12 h in 5 mM 6-mercapto-389 1-hexanol in PBS to coat the remaining gold surface. After this, 390 the sensor was rinsed with deionized water and stored in PBS.
391
Electrochemical Data Acquisition and Processing. 392 The sensors were interrogated via square wave voltammetry by 393 sweeping the electrode potential from 0.0 V to −0.5 V versus 394 Ag/AgCl, using an amplitude of 50 mV, potential step sizes of 395 1−5 mV, and varying frequencies from 10 to 500 Hz. The files 396 corresponding to each voltammogram were recorded in serial 397 order using macros in CH Instruments software. All square 398 wave measurements were performed using a three-electrode 399 setup as described above and with a CH Instruments 400 Electrochemical workstation (Austin, TX, model 1040C). 401 Postexperiment data processing was carried out in Igor Pro v.7 402 software. Images were assembled using Adobe Creative Cloud 403 Illustrator using EPS files exported from Igor Pro. simulated rapid drug elimination kinetics in this "glass rat").
435
We then instructed the controller to hold E-AB-measured drug 
